Skip to main content
德源药业 logo

德源药业 — Investor Relations & Filings

Ticker · 920735 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 569 across all filing types
Latest filing 2024-12-22 Board/Management Inform…
Country CN China
Listing Beijing Stock Exchange 920735

About 德源药业

http://www.pharmdy.com

Deyuan Pharmaceutical specializes in the research, development, production, and commercialization of therapeutic drug preparations. The company focuses on chronic disease management, particularly in the fields of endocrinology and cardiovascular health. Its core product line includes treatments for diabetes, hypertension, and hyperlipidemia, featuring medications such as Metformin Hydrochloride sustained-release tablets, Pioglitazone Hydrochloride, and Valsartan. The organization emphasizes technological innovation and maintains rigorous quality control standards across its manufacturing processes. By leveraging advanced formulation technologies, the company develops high-efficacy pharmaceutical solutions aimed at addressing the long-term needs of patients with metabolic and circulatory disorders.

Recent filings

Filing Released Lang Actions
第四届董事会第九次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolutions passed at the ninth meeting of the fourth board of directors of Jiangsu Deyuan Pharmaceutical Co., Ltd. It details the meeting's attendance, agenda items, voting results, and references related announcements published on the Beijing Stock Exchange website. The content focuses on board meeting decisions and governance matters, such as related party transactions and internal management systems. There is no financial data, earnings information, or report publication mentioned. The document is clearly a board meeting resolution announcement, which fits the category of Board/Management Information (MANG). The document length is short (1812 characters), and it is not an announcement of a report publication but the actual meeting resolutions. Therefore, the correct classification is MANG with high confidence.
2024-12-22 Chinese
关于关联交易合同主体变更的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding a change in the contracting party for related party transactions involving the company. It details the background of the related party contracts, the change in contract subject, the related parties involved, the board meeting resolutions approving the change, and the impact on the company. There are no financial statements or detailed financial data presented. The document is a formal disclosure of a corporate action related to related party transactions, specifically a contract subject change, and includes board approval details. It is not an annual report, audit report, earnings release, or any financial report. It is not a proxy solicitation or voting result announcement. It is a regulatory announcement about a corporate governance matter related to related party transactions. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories. The document length is 2833 characters, which is relatively short and consistent with an announcement rather than a full report.
2024-12-22 Chinese
舆论管理制度
Governance Information Classification · 95% confidence The document is titled as a "舆情管理制度" (Public Opinion Management System) issued by the company's board. It details the company's internal policy and procedures for managing public opinion and media-related crises, including organizational structure, responsibilities, principles, and confidentiality obligations. There is no financial data, no mention of financial results, no shareholder voting results, no legal proceedings update, no capital or financing update, no executive changes, no earnings release, no regulatory filing or certification, and no report publication announcement. The document is a governance-related internal policy issued by the board and approved by the board meeting. Therefore, it fits best under Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices. The document length is 3469 characters, which is sufficient for a detailed policy document. Confidence is high due to the clear nature of the content and absence of financial or regulatory filing elements.
2024-12-22 Chinese
开源证券股份有限公司关于江苏德源药业股份有限公司预计2025年日常性关联交易的专项核查意见
Regulatory Filings
2024-12-22 Chinese
关于1类新药注射用DYX116获得临床试验批准通知书的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Jiangsu Deyuan Pharmaceutical Co., Ltd. regarding the receipt of a clinical trial approval notice for a new drug injection DYX116 from the National Medical Products Administration. It details the drug's basic information, approval status, and risk warnings related to clinical trials and drug development. The document is short (1077 characters) and serves as an official notification of regulatory approval rather than a detailed report or financial filing. It does not contain financial data, management discussion, or detailed regulatory filings beyond the announcement itself. Therefore, it fits best into the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2024-12-19 Chinese
关于依折麦布片获国家药监局签发药品注册证书的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Jiangsu Deyuan Pharmaceutical Co., Ltd. regarding the approval and issuance of a drug registration certificate by the National Medical Products Administration (NMPA) for a pharmaceutical product (Ezetimibe tablets). It includes details about the drug, its clinical benefits, and the impact on the company. The document is short (1163 characters) and serves as an official announcement of regulatory approval rather than a detailed financial or operational report. There is no financial data, no management discussion, no earnings information, or any other report content. Therefore, it fits best as a Regulatory Filing (RNS), which is a general regulatory announcement category for filings that do not fit other specific categories.
2024-12-01 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.